Select Bibliography

Filter by any of these (after searching):

Dueck, Amylou C

There are 52 items

Clinician vs Patient Reporting of Baseline and Postbaseline Symptoms for Adverse Event Assessment in Cancer Clinical Trials

Atkinson, Thomas M. , Dueck, Amylou C. , Satele, Daniel V. ... - - JAMA Oncol - 2020

Manuscript - Secondary - Meta-Analysis - Health Outcome - N0591

Comparison Between Clinician- and Patient-Reporting of Baseline (BL) and Post-BL Symptomatic Toxicities in Cancer Cooperative Group Clinical Trials (NCCTG N0591 [Alliance])

Atkinson, Thomas M. , Satele, Daniel V. , Sloan, Jeff A. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Secondary - Primary - Health Outcome - N0591

Age and the Risk of Paclitaxel‐Induced Neuropathy in Women with Early‐Stage Breast Cancer (Alliance A151411): Results from 1,881 Patients from Cancer and Leukemia Group B (CALGB) 40101

Barginear, Myra , Dueck, Amylou C. , Allred, Jacob B. ... - - Oncologist - 2019

Manuscript - Primary - Primary - Older Adult - A151411 , CALGB-40101 , CALGB-70301

Composite Grading Algorithm for the National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Basch, Ethan , Becker, Claus , Rogak, Lauren J. , Schrag, Deborah ... - - Clin Trials - 2021

Manuscript - Secondary-not-in-original - Primary - Health Outcome - A091105

Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials

Basch, Ethan , Dueck, Amylou C. , Rogak, Lauren J. ... - - JAMA Oncol - 2017

Manuscript - Secondary-not-in-original - Meta-Analysis - Health Outcome - CALGB-30607 , CALGB-30610 , CALGB-40502 , CALGB-40503 , CALGB-40601 , CALGB-70604 , CALGB-70501 , CALGB-80405 , CALGB-90401

Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048

Basch, Ethan , Dueck, Amylou C. , Rogak, Lauren J. ... - - J. Clin. Oncol - 2018

Manuscript - Secondary-not-in-original - Primary - Health Outcome - N1048

Clinical Utility and User Perceptions of a Digital System for Electronic Patient-Reported Symptom Monitoring During Routine Cancer Care: Findings From the PRO-TECT Trial

Basch, Ethan , Stover, Angela M. , Schrag, Deborah , Chung, Arlene ... - - JCO Clin Cancer Inform - 2020

Manuscript - Primary - Primary - Health Outcome - AFT-39

Association between adaptive immune signature and outcome in HER2-positive breast cancer treated with trastuzumab and lapatinib in the NCCTG-N9831 (Alliance) and NeoALTTO trials

Chumsri, Saranya , Serie, Daniel , Mashadi-Hossein, Afshin ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original - Primary - GI - N9831

Perceived Risk for Cancer Progression and Psychological Status in Chronic Lymphocytic Leukemia Patients: CALGB 70603 (Alliance)

Deshields, Teresa , Dueck, Amylou C. , Rogers, Kerry ... - - Leuk. Lymphoma - 2019

Manuscript - Primary - Primary - Health Outcome - CALGB-70603 , CALGB-10501

Composite Grading Algorithm for the National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Dueck, Amylou C. , Becker, Claus , Rogak, Lauren J. , Schrag, Deborah ... - ASCO - J Clin Oncol - 2020

Abstract - Secondary - Preliminary - Health Outcome - A151925 , A091105 , COMET-2

Quality of life (QOL) among patients (pts) with HER2+ breast cancer (bc) treated with adjuvant lapatinib and/or trastuzumab in the ALTTO study (BIG 2-06, Alliance N063D).

Dueck, Amylou C. , Hillman, David W. , Kottschade, Lisa A. ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary-not-in-original - Primary - Breast - N063D

Validity and Reliability of the U.S. National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Dueck, Amylou C. , Mendoza, Tito R. , Mitchell, Sandra A. ... - - JAMA Oncol - 2015

Manuscript - Primary - Primary - Health Outcome - NCT02158637

A cluster-randomized study of clinician-patient shared vs standard reporting of symptomatic adverse events using PRO-CTCAE nested in a multicenter trial of multimodal therapy for rectal cancer (Alliance N1048 PROSPECT)

Dueck, Amylou C. , Mitchell, S.A. , Rogak, Lauren I. , Ginos, Brenda ... - ISOQOL - Qual Life Res - 2015

Abstract - Secondary - Primary - GI - N1048

Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831

Dueck, Amylou C. , Reinholz, Monica M. , Geiger, Xochiquetzal J. ... - - Clin. Cancer Res. - 2013

Manuscript - Secondary - Primary - Breast - N9831

Patient-reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in NCCTG (Alliance) N1031 (Randomized Phase II Study of Two Doses of Pixantrone in Patients with Metastatic Breast Cancer)

Dueck, Amylou C. , Sideras, Kostandinos , Sloan, Jeff ... - ISOQOL - Quality of Life Research - 2013

Abstract - Secondary - Primary - Breast - N1031

Sorafenib for Advanced and Refractory Desmoid Tumors

Gounder, Mrinal M. , Mahoney, Michelle R. , Van Tine, Brian A. ... - - N. Engl. J. Med. - 2018

Manuscript - Primary - Primary - Experimental - A091105

Phase III, randomized, double blind, placebo (P)-controlled trial of sorafenib (S) in desmoid tumor, (DT) (ALLIANCE A091105)

Gounder, Mrinal M. , Mahoney, Michelle R. , Van Tine, Brian Andrew ... - ASCO - J Clin Oncol - 2018

Abstract - Primary - Primary - Experimental - A091105

Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance).

Haddad, Tufia C , He, Jun , O'Sullivan, Ciara C , Chen, Beiyun ... - - Breast Cancer Res Treat - 2021

Manuscript - Primary - Primary - Breast - N0733

Randomized phase II trial of capecitabine and lapatinib with or without cixutumumab in patients with HER2+ breast cancer previously treated with trastuzumab and an anthracycline and/or a taxane: NCCTG N0733 (Alliance).

Haluska, Paul , Bernath, Albert M. , Ballman, Karla V. ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary - Primary - Breast - N0733

Radiotherapy and Adjuvant Trastuzumab in Operable Breast Cancer: Tolerability and Adverse Event Data From the NCCTG Phase III Trial N9831

Halyard, Michele Y. , Pisansky, Thomas M. , Dueck, Amylou C. ... - - J Clin Oncol - 2009

Manuscript - Secondary - Primary - Breast - N9831

Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8

Kearns, Ann E. , Northfelt, Donald W. , Dueck, Amylou C. ... - - Support Care Cancer - 2010

Manuscript - Primary - Primary - Symptom Inter - N01C8

Musculoskeletal side effects over time and the association of side effects and adherence in women taking neoadjuvant letrozole for estrogen receptor positive DCIS (CALGB 40903)

Kimmick, Gretchen , Dueck, Amylou C. , Shelby, Rebecca ... - SABCS - Cancer Res - 2020

Abstract - Secondary - Primary - Health Outcome - CALGB-40903

Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5.

Loprinzi, Charles L , Kugler, John W , Barton, Debra L ... - - J. Clin. Oncol. - 2007

Manuscript - Primary - Primary - Symptom Inter - N03C5

Combining Survival and Toxicity Effect Sizes from Clinical Trials: NCCTG 89-20-52 (Alliance)

Major-Elechi, Brittny T. , Novotny, Paul J. , Singh, Jasvinder A. ... - - Int J Stat Med Res - 2018

Manuscript - No-Endpoint - Other - Health Outcome - NCCTG-89-20-52

PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer

Mayer, Erica L. , Gnant, Michael , DeMichele, Angela , Martin, Miguel ... - ESMO - Annals of Oncology - 2020

Abstract - Primary - Primary - Breast - AFT-05

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.

Mayer, Erica L , Dueck, Amylou C , Martin, Miguel , Rubovszky, Gabor ... - - Lancet Oncol - 2021

Manuscript - Primary - Primary - Breast - AFT-05

How Much Missing Data is Too Much? Monte Carlo Simulations to Develop SISAQOL Guidelines for Missing Data Handling.

Mazza, Gina L. , Coens, Corneel , Pe, Madeline , Dorme, Lien ... - ISOQOL - Qual Life Res - 2018

Abstract - No-Endpoint - Other - Health Outcome - N07C2

Incorporating Clinicians’ CTCAE Grades as Auxiliary Variables When Imputing Patients’ PRO-CTCAE Scores via Multiple Imputation in Alliance A091105

Mazza, Gina L. , Petersen, Molly M. , Rogak, Lauren J. ... - ISOQOL - Quality of Life Research - 2020

Abstract - Secondary - Primary - Health Outcome - A151925 , A091105

Central Pathology Laboratory Review of HER2 and ER in Early Breast Cancer: An ALTTO Trial [BIG 2-06 / NCCTG N063D (Alliance)] Ring Study

McCullough, Ann E. , Dell'Orto, Patrizia , Reinholz, Monica M. ... - - Breast Cancer Res. Treat. - 2014

Manuscript - Secondary - Primary - Correl Sci NOS - N063D

The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831

Perez, Edith A. , Baehner, Frederick L. , Butler, Steven M. ... - - Breast Cancer Res - 2015

Manuscript - Secondary - Primary - Breast - NCCTG-N9831

Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial

Perez, Edith A. , Dueck, Amylou C. , McCullough, Ann E. ... - - J. Clin. Oncol. - 2013

Manuscript - Secondary - Primary - Breast - N9831

Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria

Perez, Edith A. , Dueck, Amylou C. , McCullough, Ann E. ... - - J Natl Cancer Inst - 2012

Manuscript - Secondary - Primary - Breast - N9831

Disease-free survival (DFS) and treatment effect estimates of the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance]; N063D) in the adjuvant treatment of HER2-positive early breast cancer (EBC) patients according to hormone receptor status

Perez, Edith A. , Holmes, Eileen , Baselga, José ... - ESMO - Ann. Oncol. - 2014

Abstract - Secondary - Primary - Breast - N063D

C-MYC Alterations and Association With Patient Outcome in Early-Stage HER2-Positive Breast Cancer From the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial

Perez, Edith A. , Jenkins, Robert B. , Dueck, Amylou C. ... - - J Clin Oncol - 2011

Manuscript - Secondary - Primary - Breast - N9831

HER2 and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial

Perez, Edith A. , Reinholz, Monica M. , Hillman, David W. ... - - J Clin Oncol - 2010

Manuscript - Secondary - Primary - Breast - N9831

Association of genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial.

Perez, Edith A. , Thompson, E. Aubrey , Anderson, S. Keith ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary-not-in-original - Primary - Breast - N9831

Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial

Perez, Edith A. , Thompson, E. Aubrey , Ballman, Karla V. ... - - J. Clin. Oncol - 2015

Manuscript - Secondary - Primary - Breast - N9831

First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).

Piccart-Gebhart, Martine J. , Holmes, Andrew Peter , Baselga, Jose ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary - Primary - Breast - N063D

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

Piccart-Gebhart, Martine , Holmes, Eileen , Baselga, José ... - - J. Clin. Oncol - 2016

Manuscript - Primary - Primary - Breast - N063D

Tolerability and Toxicity of Trastuzumab or Trastuzumab + Lapatinib in Older Patients

Ponde, Noam Falbel , Agbor-Tarh, Dominique , Lago, Lissandra Dal ... - ASCO - JCO - 2019

Abstract - Secondary-not-in-original - Primary - Breast - N063D

Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D).

Pondé, Noam , Agbor-Tarh, Dominique , Dal Lago, Lissandra ... - - Breast Cancer Res Treat - 2021

Manuscript - Secondary-not-in-original - Primary - Breast - N063D

IGF1R Protein Expression is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2-positive Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831

Reinholz, Monica M. , Chen, Beiyun , Dueck, Amylou C. ... - - Clin. Cancer Res. - 2017

Manuscript - Secondary - Primary - Breast - NCCTG-N9831

Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group (NCCTG) trials, N0234/336/436/437

Reinholz, Monica M. , Kitzmann, Kathleen A. , Tenner, Kathleen ... - - Clin. Cancer Res. - 2011

Manuscript - Secondary-not-in-original - Primary - Breast - N0336 , N0234 , N0338 , N0436 , N0437

Cost of chemotherapy for metastatic colorectal cancer with either bevacizumab or cetuximab: Economic analysis of CALGB/SWOG 80405.

Schrag, Deborah , Dueck, Amylou C. , Naughton, Michelle Joy ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Secondary - Primary - Health Outcome - CALGB-70502 , CALGB-80405

North Central Cancer Treatment Group (NCCTG) N0537: Phase II Trial of VEGF-Trap in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and/or a Taxane

Sideras, Kostandinos , Dueck, Amylou C. , Hobday, Timothy J. ... - - Clin. Breast Cancer - 2012

Manuscript - Primary - Primary - Breast - NCCTG-N0537

Combining survival and toxicity effect sizes from clinical trials into an interpretable, quality-adjusted survival effect size estimate of treatment efficacy.

Sloan, Jeff A. , Major, Brittny , Novotny, Paul J. , Grothey, Axel ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary-not-in-original - Primary - Symptom Inter - NCCTG-89-20-52

Scientific imperatives, clinical implications, and theoretical underpinnings for the investigation of the relationship between genetic variables and patient-reported quality-of-life outcomes

Sprangers, Mirjam A. G. , Sloan, Jeff A. , Barsevick, Andrea ... - - Qual Life Res - 2010

Manuscript - Secondary-not-in-original - Comprehensive - Health Outcome - N9741

Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in CALGB 50401 (Alliance)

Thanarajasingam, Gita , Leonard, John P. , Witzig, Thomas E. ... - - Lancet Haematol - 2020

Manuscript - No-Endpoint - Other - Health Outcome - A151617 , CALGB-50401

Impact of Adjuvant Trastuzumab on Local-regional Failure Rates in the NCCTG N9831 (Alliance) Study

Thorpe, Cameron S. , Vargas, Carlos E. , Dueck, Amylou C. ... - ASTRO - International Journal of Radiation Oncology • Biology • Physics - 2019

Abstract - Secondary-not-in-original - Primary - Breast - N9831

Impact of Adjuvant Trastuzumab on Locoregional Failure Rates in the Randomized Clinical Trial: NCCTG N9831 (Alliance) Study

Vargas, Carlos E. , Thorpe, Cameron S. , Dueck, Amylou C. ... - - Cancer - 2020

Manuscript - Secondary-not-in-original - Primary - Breast - N9831

Expanding Beyond Maximum Grade: Chemotherapy Toxicity over Time by Age and Performance Status in Advanced Non‐Small Cell Lung Cancer in CALGB 9730 (Alliance A151729)

Wong, Melisa L. , Gao, Junheng , Thanarajasingam, Gita ... - - Oncologist - 2021

Manuscript - Primary - Primary - Older Adult - A151729 , CALGB-9730

Comparison of chemotherapy toxicity over time according to age and performance status in patients with advanced non-small cell lung cancer: a toxicity over time analysis of CALGB 9730 (Alliance A151729)

Wong, Melisa L. , Gao, Junheng , Thanarajasingam, Gita ... - SIOG (ISOG) - J Geriatric Oncol - 2018

Abstract - Primary - Primary - Older Adult - CALGB-9730